- Investor's Business Daily
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
Immunovant stock slumped Thursday — reversing a day-earlier jump — after pivoting its focus to what one analyst called "a backup compound."
- Zacks
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.
- Investor's Business Daily
Biohaven Tumbles After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
Biohaven stock tumbled Wednesday after the company's experimental protein-degrading drug lagged investor expectations.
